INDIA CORONARY STENTS MARKET ANALYSIS

Market News

India Coronary Stents Market: Key Developments

Major players in the market are focused on performing clinical trials of their products to introduce them in market and expand their product portfolio. For instance, according to article published on October 15, 2022 in American journal of Cardiovascular disease, a clinical study was conducted to evaluate the  safety and effectiveness of ultrathin (60 µm), biodegradable polymer-coated Tetriflex sirolimus-eluting stent (SES) developed by Sahajanand Medical Technologies Limited, gobal developer and manufacturer of minimally invasive cardiovascular devices. As per the results, favorable clinical outcomes were observed in Tetriflex SES with low incidence of target lesion failure (TLF)  and stent thrombosis in high-risk diabetes patients.

The use of a balloon stent coated with paclitaxel and iopromide is preferred over bare-metal stents in patients with high bleeding risk undergoing PCI. According to the results of the single-blind, randomized, noninferiority DEBUT trial conducted by researchers from Harvard Medical School and published in The Lancet in May 2019, PCI with drug-eluting balloons is noninferior to PCI with bare-metal stents for treatment of de novo coronary artery lesions in patients with high bleeding risk.    

Key market players are adopting strategies like acquisition which are fueling the growth of India Coronary stent market. For instance, in January 19, 2023 Kotak Pre- IPO, a later stage venture capital fund managed by Kotak Investment Advisors aquired a stake in Sahajanand Medical Technologies, India based stent manufacturing company for US$ 20.7 million. The fund has acquired about 6% stake in SMT.